Synaptogenix (NASDAQ:SNPX) Releases Earnings Results

Synaptogenix (NASDAQ:SNPXGet Free Report) announced its quarterly earnings data on Thursday. The company reported ($4.36) earnings per share for the quarter, Zacks reports.

Synaptogenix Stock Performance

Shares of NASDAQ SNPX opened at $2.67 on Friday. The company’s fifty day moving average is $2.96 and its two-hundred day moving average is $3.02. Synaptogenix has a one year low of $2.15 and a one year high of $6.22.

Synaptogenix Company Profile

(Get Free Report)

Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It also evaluates therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease.

Recommended Stories

Earnings History for Synaptogenix (NASDAQ:SNPX)

Receive News & Ratings for Synaptogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synaptogenix and related companies with MarketBeat.com's FREE daily email newsletter.